

## RESOLUTION

Subject: Review of 201 KAR 9:270

Submitted by: Greater Louisville Medical Society

Referred to: Reference Committee

---

WHEREAS, according to the 2024 Kentucky Drug Overdose Fatality Report, 1,410 Kentuckians lost their lives last year to a drug overdose<sup>1</sup>; and

WHEREAS, buprenorphine treatment<sup>2</sup> has been associated with an approximate 60% reduction in the risk of opioid-involved overdose death; and

WHEREAS, 201 KAR 9:270 is a recognized barrier<sup>3</sup> to patients accessing treatment with buprenorphine; and

WHEREAS, the Kentucky Society of Addiction Medicine (KYSAM) and other field experts, have reviewed the Kentucky Board of Medical Licensure's (KBML) proposed changes to 201 KAR 9:270 and have concluded that the proposed changes will create environments unattractive to patients because of unnecessary and unhelpful regulatory burdens and will not bring the regulation in accord with evidence-based practice<sup>4</sup>, but will instead create new treatment barriers and may even worsen Kentucky's overdose crisis; and

WHEREAS, in August 2024 the Kentucky Medical Association House of Delegates passed resolution 2024-12.2, calling for the same "RESOLVED" actions stated below; now, therefore, be it

RESOLVED, that KMA continues to support the implementation of effective and accessible treatment options for those addicted to opioids; and be it further

RESOLVED, that KMA continues to support the use of Buprenorphine as a vital tool in combating opioid use disorder; and be it further

RESOLVED, that KMA continues to support the KBML's outreach to and use of a broad array of subject matter experts, as well as accepted clinical standards and guidelines, to revise and update regulations regarding the use of Buprenorphine in treating those addicted to opioids; and be it further

RESOLVED, that KMA continues to encourage the KBML to seek a broader input of practitioners and content experts prior to finalizing the regulatory changes to 201 KAR 9:270.

**References:**

---

1. Kentucky 2024 Drug Overdose Fatality Report, Kentucky Office of Drug Control Policy  
<https://odcp.ky.gov/Reports/2024%20Drug%20Overdose%20Fatality%20Report.pdf>
2. Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. American Journal of Preventive Medicine. Vol 65, Issue 1, P19-29, July 2023 [https://www.ajpmonline.org/article/S0749-3797\(23\)00052-1/abstract#:~:text=Buprenorphine%20treatment%20after%20nonfatal%20opioid,of%20opioid%2Dinvolved%20overdose%20death](https://www.ajpmonline.org/article/S0749-3797(23)00052-1/abstract#:~:text=Buprenorphine%20treatment%20after%20nonfatal%20opioid,of%20opioid%2Dinvolved%20overdose%20death)
3. Improving Access to Opioid Use Disorder Treatment in Kentucky. The Pew Charitable Trusts  
<https://odcp.ky.gov/Resources/Documents/Pew%20Kentucky%20Memo%20FINAL.pdf>
4. KYSAM Comments on 201 KAR 9:270 Proposed Regulations, July 27, 2025  
<https://files.constantcontact.com/8e65fc57801/843d95e5-2dd6-4ca1-8958-36bc7c11d637.pdf?rdr=true>